Kala Pharmaceuticals, Inc. (KALA)
Largest Insider Buys in Sector
KALA Stock Price History Chart
KALA Stock Performance
About Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative …
Insider Activity of Kala Pharmaceuticals, Inc.
Over the last 12 months, insiders at Kala Pharmaceuticals, Inc. have bought $0 and sold $323,513 worth of Kala Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Kala Pharmaceuticals, Inc. have bought $240.12M and sold $565,144 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 80 shares for transaction amount of $304 was made by Bazemore Todd (Chief Operating Officer) on 2020‑10‑22.
List of Insider Buy and Sell Transactions, Kala Pharmaceuticals, Inc.
| 2024-06-26 | Sale | CHIEF EXECUTIVE OFFICER | 15,168 0.5561% | $4.75 | $72,048 | +28.37% | ||
| 2024-06-26 | Sale | SEE REMARKS | 5,489 0.2012% | $4.75 | $26,073 | +28.37% | ||
| 2024-06-26 | Sale | SEE REMARKS | 4,653 0.1706% | $4.75 | $22,102 | +28.37% | ||
| 2024-06-26 | Sale | CHIEF FINANCIAL OFFICER | 4,163 0.1526% | $4.75 | $19,774 | +28.37% | ||
| 2024-06-26 | Sale | CHIEF BUSINESS OFFICER | 5,158 0.1891% | $4.75 | $24,501 | +28.37% | ||
| 2024-05-31 | Sale | CHIEF EXECUTIVE OFFICER | 7,392 0.2379% | $6.09 | $45,017 | -12.05% | ||
| 2024-05-31 | Sale | SEE REMARKS | 2,002 0.0644% | $6.09 | $12,192 | -12.05% | ||
| 2024-05-31 | Sale | SEE REMARKS | 2,093 0.0673% | $6.09 | $12,746 | -12.05% | ||
| 2024-05-31 | Sale | CHIEF BUSINESS OFFICER | 231 0.0074% | $6.09 | $1,407 | -12.05% | ||
| 2024-05-31 | Sale | CHIEF FINANCIAL OFFICER | 1,786 0.0575% | $6.09 | $10,877 | -12.05% | ||
| 2024-01-04 | Sale | CHIEF EXECUTIVE OFFICER | 4,539 0.1618% | $6.73 | $30,547 | -2.43% | ||
| 2024-01-04 | Sale | SEE REMARKS | 1,617 0.0577% | $6.74 | $10,899 | -2.43% | ||
| 2024-01-04 | Sale | SEE REMARKS | 1,227 0.0438% | $6.74 | $8,270 | -2.43% | ||
| 2024-01-04 | Sale | CHIEF FINANCIAL OFFICER | 1,227 0.0438% | $6.74 | $8,270 | -2.43% | ||
| 2024-01-04 | Sale | CHIEF BUSINESS OFFICER | 1,385 0.0494% | $6.73 | $9,321 | -2.43% | ||
| 2024-01-04 | Sale | SEE REMARKS | 1,405 0.0502% | $6.74 | $9,470 | -2.43% | ||
| 2023-01-04 | Sale | CHIEF EXECUTIVE OFFICER | 198 0.0065% | $28.54 | $5,651 | -66.29% | ||
| 2023-01-04 | Sale | SEE REMARKS | 73 0.0024% | $28.53 | $2,083 | -66.29% | ||
| 2023-01-04 | Sale | SEE REMARKS | 62 0.002% | $28.54 | $1,769 | -66.29% | ||
| 2023-01-04 | Sale | CHIEF FINANCIAL OFFICER | 60 0.002% | $28.54 | $1,712 | -66.29% |
Insider Historical Profitability
| Bazemore Todd | SEE REMARKS | 83040 1.8023% | $7.00 | 3 | 9 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10874613 236.0162% | $7.00 | 3 | 0 | <0.0001% | |
| Shah Rajeev M. | 7039613 152.7836% | $7.00 | 3 | 2 | <0.0001% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 3447840 74.8299% | $7.00 | 14 | 0 | <0.0001% |
| Grunberg Gregory | director | 2534854 55.015% | $7.00 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $2.12M | 5.98 | 266,613 | 0% | +$0 | 0.02 | |
| Millennium Management LLC | $1.05M | 2.99 | 133,403 | +0.55% | +$5,715.36 | <0.01 | |
| Ubs Oconnor Llc | $568,823.00 | 1.63 | 72,554 | New | +$568,823.00 | 0.03 | |
| The Vanguard Group | $334,589.00 | 0.94 | 41,981 | +49.74% | +$111,149.76 | <0.0001 | |
| BlackRock | $216,601.00 | 0.61 | 27,177 | -0.53% | -$1,147.68 | <0.0001 |